Markers and Response to Cardiac Resynchronization Therapy (MARC)
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
This observational or N/A phase trial investigates Heart Failure and is currently completed. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) leads this study, which shows 11 recorded versions since 2012 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2024 — Jul 2024 [monthly]
Completed
-
Dec 2021 — May 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Center for Translational Molecular Medicine
- Free University Medical Center
- Maastricht University Medical Center
- UMC Utrecht
- University Medical Center Groningen
For direct contact, visit the study record on ClinicalTrials.gov .